Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
NCT06602011
·
clinicaltrials.gov ↗
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
COMBINATION_PRODUCT:
TACE, Lenvatinib, combined with Tislelizumab group
Sponsor
Fujian Provincial Hospital